Dupilumab Approved by EMA for COPD Treatment in Europe
On July 3rd, 2024, Sanofi and Regeneron jointly announced that their co-developed drug, dupilumab (brand name: Dupixent), has successfully gone through the approval process of the European Medicines Agency (EMA) and been authorized for the treatment of adult patients with COPD (Chronic Obstructive Pulmonary Disease) who have a high blood eosinophil count and whose disease is not adequately controlled with inhaled corticosteroids (ICS), long-acting beta2-agonists (LABA), and long-acting muscarinic antagonists (LAMA) triple therapy, or with LABA and LAMA dual therapy when ICS is not suitable.
This broad approval marks a significant breakthrough in COPD treatment in the European Union, as Dupixent is the first targeted therapy approved for COPD patients. COPD is a highly prevalent chronic respiratory disease characterized by airflow limitation and lung inflammation, which significantly impacts patients' quality of life. Despite the availability of various treatment options, COPD patients still face the challenges of recurrent acute exacerbations and high healthcare costs.
Dupilumab, a fully human monoclonal antibody, works by specifically blocking the signaling pathways of interleukin-4 (IL-4) and interleukin-13 (IL-13), reducing the inflammatory response and alleviating COPD symptoms. These two cytokines play a crucial role in the pathogenesis of COPD, and their overexpression leads to worsening lung inflammation and function decline.
It is worth noting that during the approval process with the U.S. Food and Drug Administration (FDA), the agency requested a deeper analysis of the efficacy data from the Phase III BOREAS and NOTUS studies. As a result, the PDUFA (Prescription Drug User Fee Act) date for Dupixent in the U.S. has been delayed from the original June 27th, 2024, to September 27th, 2024. However, Sanofi and Regeneron have proactively responded by submitting the additional data required by the FDA in early May, hoping to expedite the approval in the United States.
The approval of Dupixent in Europe provides a new treatment option for COPD patients, offering the potential for more targeted and effective management of their condition and improved quality of life.
2026-10-28
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FSANZ Moves Toward Approval of Insect-Resistant Corn COR121
-
Thymol Gel Wins EPA Approval for Beekeepers
-
U.S. Formally Imposes Antidumping and Countervailing Duty Orders on Chinese L-Lysine
-
FDA Slows Two Natural Color Approvals, but the Additive Shift Is Still Moving
-
The FDA Officially Blesses AI for Liver Drug Development
-
U.S. FDA Opens New Safety Review of RSV Treatments for Infants
-
3M, DuPont and Honeywell Must Face Firefighters’ PFAS Turnout-Gear Lawsuit
-
FDA Slams Door on Chinese Food Exports: Inspection Refusals Trigger Automatic Detentions
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
U.S. Section 232 Pharmaceutical Tariffs Take Effect, With 100% Base Rate on Patented Drugs and APIs
Recommend Reading
-
“No Artificial Colors” Gets Redefined—Why FDA’s Labeling Shift Is Roiling the Food Additive World
-
FDA Reopens BHA Review—Why One Preservative Is Becoming a Global Wake-Up Call for Food Additives
-
EFSA’s Updated Food-Additive Application Guidance Takes Effect
-
India Approves ₹30.3 Billion Chemical-Park Scheme to Build Three Mega Industrial Hubs
-
FDA Revokes Orange B Authorization and Proposes Removing Citrus Red No. 2
-
Geopolitical Risks Escalate, Acrylonitrile Prices Rise Driven by Cost Increases in China
-
Butadiene Rubber Market Prices Rise Sharply
-
Polyester Bottle Flakes Remain Highly Volatile This Week; Weekly Average Price Rises Compared to Previous Week
-
Geopolitical Tensions Intensify, Causing a Significant Increase in Polyester Chip Prices
-
This Week's PVC Market in China: Bottoming Out with Low-level Fluctuations, Intensifying Supply and Demand Competition